AVGO vs LLY: Which Is the Better Buy?
Side-by-side comparison of Broadcom Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Broadcom Inc. · Technology
$354.99
+15.1% upside to fair value
Med Conviction
Grade B
High Quality
VS
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
AVGO has more upside to fair value
(+15.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AVGO |
LLY |
| Current Price |
$354.99 |
$1,183.72 |
| Fair Value Estimate |
$408.70 |
$1,208.00 |
| Upside to Fair Value |
+15.1%
|
+2.1%
|
| Market Cap |
$1,688.9B |
$1,114.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
33.0x
|
26.8x
|
| Price / Sales |
18.9x
|
14.0x
|
| Price / FCF |
42.9x
|
52.7x
|
| Revenue Growth YoY |
+85.5%
|
+47.7%
|
| Gross Margin |
67.7%
|
83.4%
|
| Operating Margin |
48.3%
|
49.7%
|
| Return on Equity |
43.9%
|
92.6%
|
| Dividend Yield |
0.73% |
0.57% |
| FCF Yield |
2.33%
|
1.9%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Broadcom is a diversified semiconductor and infrastructure software company led by CEO Hock Tan, with a portfolio spanning custom AI ASICs, networking, wireless, storage, and enterprise software. The business quality is high: TTM gross margin of 67.7%, TTM operating margin of 48.3%, TTM net margin of 42.9%, and ROE of 43.9% demonstrate exceptional profitability, while revenue growth of 85.5% and …
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Accumulation Zones
| Metric |
AVGO |
LLY |
| Zone Low |
$306.52 |
$906.00 |
| Zone High |
$347.39 |
$1,026.80 |
| In Buy Zone? |
No
|
No
|